NATtrol™ Respiratory Verification Panel 2 (21 x 0.25mL) (EA)
(0 avis)

1 550,00 € 1550.0 EUR 1 550,00 € hors TVA

1 550,00 € hors TVA

Not Available For Sale

    Cette combinaison n'existe pas.

    Conditions générales
    Garantie satisfait ou remboursé de 30 jours
    Expédition : 2-3 jours ouvrables


    NATtrol™ Respiratory Verification Panel 2 (qualitative)* is formulated with purified, intact bacterial/fungal cells and viral particles that have been chemically modified to render them non-infectious and refrigerator stable. NATRVP2-QIA contains 20 x 0.25 mL vials of bacterial, fungal, or viral NATtrol™ and 1 x 0.25 mL vial of negative (matrix only) as listed in Table 1. The panel members are supplied in a proprietary matrix.



    • NATtrol™ Respiratory Verification Panel 2 is designed to evaluate the performance of nucleic acid tests for determination of the presence of bacterial, fungal, and nucleic acids (from organisms listed in Table 1). NATRVP2-QIA can also be used for validation of clinical assays, development of diagnostic tests and training of laboratory personnel.  


    • NATtrol™ inactivation was carried out on microorganism stocks used to formulate the panel members. The inactivation was verified in standard microbiological growth protocol. 

    • This panel contains inactivated microorganisms and materials of human and animal origin. Safe practices suggest that the controls be considered potentially infectious and to use Universal Precautions when handling. 

    • Refer to CDC guidelines and local regulations for handling and disposal. 

    • The matrix used in the manufacture of this product is treated with 0.09% sodium azide. It was manufactured from Human Serum Albumin that has been tested and found non-reactive at the donor level for HIV-1/HIV-2 Antibody, HBsAg and HCV Antibody by FDA licensed donor screening test methods. All materials are also tested for HIV-1 and HCV by FDA approved Nucleic Acid Test (NAT) methods. 

    • Heat inactivated Fetal Bovine Serum used in the manufacture of this product meets applicable USDA requirements for abattoir sourced animals, traceability and country of origin. The materials were collected at USDA licensed establishments or legally imported from countries recognized by the USDA as negligible or controlled for risk for Bovine Spongiform Encephalopathy (BSE) and other exotic disease agents. Donor animals were inspected ante and post mortem at the abattoir as required by the USDA. 

    • Do not use past the expiration date on the label. 

    • To avoid cross-contamination, use separate pipette tips for all materials.


    • NATtrol™ Respiratory Verification Panel 2 should be stored at 2- 8°C.


    • Mix vial vigorously for at least 5 secs. 

    • Process according to manufacturer’s instructions for sample to result assays. 

    • Extract nucleic acids prior to use in downstream assays that are not sample to result.



    • Quality control materials should be used in accordance with local, state, federal, and accreditation requirements. 

    • This product is not intended to replace the manufacturer’s controls provided with the assay.


    • Each laboratory must evaluate the product and establish their own acceptance criteria. 

    • This panel has been tested with the QIAstat-Dx® Respiratory SARS-CoV-2 Panel assay and provides all expected results for the panel members listed in Table 1.

    Table 1: PANEL MEMBERS 


    1-This analyte only contains a short sequence of the viral genome therefore each laboratory must evaluate performance in their assay. 

    2-Please note that although similar in nomenclature, this is a 2009 H1N1 pandemic Influenza strain and does NOT correlate with the seasonal 2009 Influenza strains found in the database. For reference, the NCBI Taxon IDs for the seasonal Influenza strains listed in the database are: A/New York/01/2009 (H1N1) - 666252; B/New York/01/2009 - 664512; A/New York/02/2009 (H1N1) - 666298; and A/New York/03/2009 (H3N2) - 659637. 

    3-This product is sold by ZeptoMetrix under license from Vironovative B. V under patent applications, including U.S. Patent Applications 10/371,099 and 10/371,12 and any patents that issue from applications related to PCT/NL02/00040 and PCT/US03/05271.” 

    4-This reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR52281.